NextFin

Delaware Life Sales Slow as U.S. Probe Tests Mark Walter’s Insurance Empire

Summarized by NextFin AI
  • Delaware Life reported $6.9 billion in first-half 2026 sales, signaling a significant slowdown even though admitted assets rose to $70.5 billion.
  • The insurer’s affiliated-investment exposure remained substantial at 39% of general-account invested assets, following disclosures of reporting errors and ongoing U.S. investigations.
  • A proposed exchange of up to $6.5 billion of investments could reduce affiliated holdings below 10% by June 2027, subject to regulatory approval and execution.
  • Current earnings, capital, and A- ratings remain resilient, but distributor caution and negative rating outlooks make sales recovery a test of confidence in Delaware Life’s governance and franchise.

NextFin News - Delaware Life reported $6.9 billion of sales for the six months ended June 30, 2026, versus $15.3 billion for all of 2025, a comparison that is not like-for-like but still places a marked slowdown beside an ongoing U.S. investigation into the insurer’s related-party investments. A Florida federal complaint filed in September alleged that at least two national bank distributors paused sales of Delaware Life annuity products in late August; the allegation has not been adjudicated. Meanwhile, Delaware Life says a TWG-linked asset-exchange plan could cut affiliated holdings from 39% of general-account invested assets to approximately 20%–25% by year-end 2026 and below 10% by June 30, 2027, subject to regulatory approval. The central question is whether weaker production is a temporary confidence shock while the company repairs its books, or evidence that the disclosure controversy has damaged the franchise that generates new annuity business.

The sales figures appear on Delaware Life’s own financial highlights page. The company reported $70.5 billion of admitted assets, $47.8 billion of invested assets, $4.0 billion of capital and surplus, $308 million of pretax operating earnings and $166 million of net income as of June 30, 2026. For full-year 2025, the corresponding figures were $64.7 billion, $42.5 billion, $3.8 billion, $558 million and $295 million. The balance sheet therefore grew while sales slowed. The immediate problem is not a demonstrated inability to meet obligations, but pressure on the future growth engine while the existing book remains large.

Delaware Life says it has more than 380,000 active annuity and life policies. Its net investment earned rate was 6.85% in the latest period, compared with 7.25% for 2025. Those figures describe a carrier still generating earnings from a substantial asset base, but they also show why regulators and ratings analysts are focused on how those assets were classified and who ultimately bears their credit risk.

On June 26, Delaware Life disclosed that a material portion of its private-credit investments had been reclassified from unaffiliated to affiliated. The company said the disclosure followed a grand-jury subpoena received in early February from the U.S. Attorney’s Office for the Southern District of New York and a parallel investigation by the Securities and Exchange Commission. Delaware Life’s September update said an internal investigation found errors in identifying and reporting certain related-party investments, whose returns were predominantly contingent on affiliate performance.

The company’s table showed affiliated assets of $18.251 billion at Dec. 31, 2025, after restatement, $19.799 billion at March 31, 2026 and $19.148 billion at June 30, 2026. Against general-account invested assets of $43.883 billion, $48.184 billion and $49.336 billion, the affiliated share was 42%, 41% and 39%, respectively. Delaware Life also said it received the outstanding principal on $0.9 billion of investments during the second quarter.

On Aug. 17, the company said it entered an agreement with TWG Global to exchange up to $6.5 billion of recently reclassified private-credit investments for an equivalent amount of non-affiliated investments. Delaware Life said the transaction could reduce the affiliated share to approximately 26% on a pro forma basis if the full exchange closes, with further purchases by TWG intended to bring the share to approximately 20%–25% by year-end and below 10% by June 30, 2027. The targets are company expectations, not regulatory mandates, and remain subject to approval.

The sales slowdown is therefore more than a weak quarter. It is a test of whether an insurer can preserve distribution momentum while asking regulators, ratings agencies and financial representatives to accept a revised picture of its investment exposure.

The Sales Shock Is Real, but the Comparison Needs Discipline

What exactly plunged? The cleanest answer is the production rate, not a precise year-over-year percentage. Delaware Life’s $6.9 billion of sales through June 30 represents about 45% of the $15.3 billion recorded in all of 2025. A simple annualization of the half-year figure would imply roughly $13.8 billion, about 10% below last year’s total, but that is an analytical yardstick, not company guidance and not a reported annual run rate.

That distinction prevents the most obvious error. A six-month figure cannot be described as a precise year-over-year collapse without a comparable six-month base. Yet the direction is difficult to dismiss. The company’s admitted-asset base rose about 9% from $64.7 billion at the end of 2025 to $70.5 billion at June 30, while total sales reached less than half of the previous full-year amount. Existing contracts and investment income can lift assets even when new business weakens; the divergence is consistent with an in-force book that keeps generating assets while advisers become more selective about placing fresh premiums.

The sales figure also has to be read alongside earnings. Pretax operating earnings of $308 million in the first half were 55% of the $558 million generated in 2025, while net income of $166 million was 56% of last year’s $295 million. On that narrow run-rate basis, earnings held up better than sales. That is not proof that the controversy is harmless. It is evidence that the immediate transmission channel runs through growth and distribution before it runs through the existing book’s reported profitability.

Delaware Life focuses on annuity and life products. In that market, new production depends on a chain longer than a policyholder’s decision: an independent agent recommends a product, a broker-dealer or platform permits the sale, a wholesaler supplies product support, and a rating agency’s financial-strength opinion helps frame the contract’s credibility. A disclosure issue can interrupt that chain even before a regulator imposes a penalty.

The distributor allegation provides a concrete example of that mechanism. The September Florida complaint said that Truist Financial Corporation and Fifth Third Bancorp had paused sales of Delaware Life annuity products in late August. That is an allegation in a civil pleading, not a judicial finding, but it shows why an accounting and governance issue can reach new business before it reaches claims-paying capacity.

The company’s ratings remained A-, but the status around them became less comfortable. Delaware Life’s own page lists A- ratings from AM Best, S&P and Fitch, with a negative outlook from AM Best, a negative outlook from S&P and a negative watch from Fitch as of July 2026. S&P affirmed its A- rating while moving the outlook to negative from stable. Fitch separately placed Delaware Life’s A- insurer financial-strength rating on Rating Watch Negative. The rating was not downgraded, yet the change turns future sales into a risk metric: if production stays weak, the decline may be interpreted not as a one-off pause but as evidence of a weakened competitive position.

The first takeaway is narrow but important. Sales have weakened enough to matter, but the available numbers do not show a contemporaneous balance-sheet crisis. The story is about confidence transmission.

The Mechanism Runs Through Distribution, Capital and Disclosure

Why would an investigation into affiliated investments reduce sales? The mechanism is not simply that customers read a headline and stop buying. It is that the information changes the cost of distribution.

Agents sell long-duration products by converting a promise about future income into a judgment about the carrier’s capacity to honor it. When affiliated assets are restated from unaffiliated to affiliated, the accounting label changes how investors, regulators and counterparties assess concentration, underwriting discipline and governance. The underlying assets do not have to default for the economics of distribution to change. The perceived probability of future friction is enough to make a distributor choose a competitor whose financial story is easier to explain.

That channel is reinforced by capital. S&P said Delaware Life’s risk-based capital ratio was 430% at the end of 2025 and affirmed the A- rating, while also emphasizing execution risk tied to remediation and the possibility of higher credit-risk charges after restructuring. A 430% ratio is a meaningful published cushion, but it is not a guarantee that capital will remain equally efficient after the portfolio is reorganized. If affiliated exposures require more conservative treatment, the company can preserve nominal capital while accepting lower returns or reducing the products it is willing to write.

Delaware Life’s own explanation captures the accounting trigger:

“Through our internal investigation, we identified errors relating to the identification and reporting of certain related-party investments.” — Delaware Life, Affiliated Investments Reduction Update, Sept. 11, 2026.

That statement does not establish misconduct, and the investigations remain unresolved. It does establish why the issue reaches beyond public relations. The company is repairing a control process that sits between investment underwriting and statutory reporting. That repair consumes management capacity, invites regulatory review and makes every new sale more dependent on the credibility of the remediation plan.

The second-order effect is on product economics. If distributors demand higher compensation for placing business with a carrier under scrutiny, or if the carrier raises liquidity and capital buffers, the cost of new production rises. The insurer can respond by offering more attractive terms, but that can compress margins. Alternatively, it can accept slower sales and protect economics. Either choice creates a trade-off between franchise repair and growth.

The asset-exchange plan shows the same tension. Delaware Life says exchanging up to $6.5 billion could reduce affiliated holdings to approximately 26% on a pro forma basis, but the company also says the result depends on how the exchanged assets are held and that the transaction requires regulatory approval. A reduction in concentration may improve the narrative around the general account. But it also makes the company dependent on execution: the replacement assets must be sufficiently high quality, the transaction must close, and the process must not create a capital or liquidity surprise.

S&P’s framework is explicit about that dependency:

“The negative outlook reflects our view that Delaware Life is facing execution risk, as it implements its remediation plan as well as the possibility of higher credit risk charges post-restructuring of investments.” — S&P Global Ratings, July 14, 2026.

This is why sales are not a secondary statistic. They are one of the external tests of whether remediation is restoring confidence. S&P said a return to stable would depend partly on sales, earnings and returns remaining consistent with the company’s business plan. A weak sales path can therefore feed back into ratings even if current assets remain sound.

The immediate effect is cyclical: distributors can pause, then return, once the company demonstrates clean reporting and completes the asset plan. The underlying governance issue is structural until management proves otherwise. A structural problem does not mean permanent failure; it means the old growth process will not automatically restart merely because market rates or annuity demand improve.

That distinction is the core judgment. The sales decline is partly a cyclical confidence shock, but the control remediation is a structural test of the franchise. Mean reversion requires evidence, not optimism.

Why the Broader Annuity Market May Not Rescue Delaware Life

Could stronger industry demand overwhelm the company-specific problem? That is the strongest counter-thesis. Annuities can attract money when investors want guaranteed income, when equity volatility raises the appeal of protection, or when market yields allow carriers to offer more compelling credited rates. If the market expands, a temporary pause at one carrier might reflect product mix or distributor timing rather than reputational damage.

That argument deserves weight because Delaware Life’s asset and earnings figures remain substantial. The company reported $47.8 billion of invested assets and $166 million of net income through June 30. Its balance-sheet figures did not contract with sales. Its ratings did not fall below A-. Its capital-and-surplus figure increased to $4.0 billion from $3.8 billion at year-end 2025. S&P also said, under its assumptions, that the restructuring would not have a meaningful impact on earnings or the risk-based capital ratio. These are not the figures of an institution facing an immediate run by policyholders.

But the counter-thesis does not answer the distribution problem. A growing market can make a carrier’s lost share more visible, not less. If industry demand remains healthy while Delaware Life’s new sales slow, the evidence shifts from “the customer is waiting” to “the customer is choosing elsewhere.” A stronger sector also gives agents more substitutes, lowering the cost of leaving a carrier under scrutiny.

The relevant comparison is not sales against zero. It is sales against the opportunity set available to distributors. A carrier with $70.5 billion of admitted assets can preserve existing earnings while losing marginal growth to competitors. That is a delayed problem: the current income statement looks stable because old contracts remain, but the future asset base grows more slowly and fixed costs spread over less new business.

The second-order cross-industry effect is on private credit. Insurers have increasingly used privately originated credit to match long-dated liabilities with assets that can offer higher yields than traditional public bonds. Delaware Life’s 6.85% net investment earned rate illustrates the attraction of that strategy. Yet the same strategy raises the value of transparent underwriting and related-party controls. If an insurer’s private-credit book becomes difficult to classify, the issue can affect how regulators view the asset class rather than just one company.

That is where the story can become structural for the sector. The regulatory response may not stop at asking Delaware Life to correct its books. Supervisors can demand clearer related-party disclosures, more robust look-through analysis of private-credit borrowers and stronger approval procedures for affiliate-linked investments. Such rules would raise compliance costs across the industry and could reduce the speed at which insurers expand private-credit allocations.

The strongest rebuttal is that the assets may perform as expected. Delaware Life said it received principal on $0.9 billion of investments predominantly contingent on affiliate performance, and S&P said the restructuring was not expected, under its assumptions, to produce a meaningful impact on earnings or the risk-based capital ratio. If replacement assets remain high quality and the investigations end without monetary penalties or adverse judgments, the controversy could fade.

That is plausible. It is not the base case for a quick return to the old growth trajectory because disclosure repair has a longer half-life than a single asset payoff. The falsifying signal for this analysis is concrete: if Delaware Life’s next comparable six-month sales disclosure returns to at least the prior comparable pace, the affiliated share falls below the company’s June 30 ratio of 39%, and all three major rating agencies remove negative outlook or watch language, then the structural-franchise thesis would be wrong. It would show that the sales shock was temporary and that remediation restored distribution confidence.

Until then, the industry-growth defense explains why the company can remain solvent and profitable. It does not explain why new business should recover.

What the Probe Changes for Policyholders and the Parent

For policyholders, the near-term question is not whether every affiliated investment will lose money. It is whether the carrier can maintain liquidity, capital and claims-paying capacity while changing the portfolio. The published figures provide some support: $4.0 billion of capital and surplus at June 30, a 430% risk-based capital ratio at the end of 2025, and A- ratings that remained in place. But those data points are historical or point-in-time measures; they do not settle the effect of future penalties, judgments or restructuring costs.

For the parent, the issue is broader. TWG Global is not merely an owner standing outside the insurer. Delaware Life’s remediation plan includes asset exchanges with TWG, and S&P said TWG would provide support through an asset-purchase agreement and capital-maintenance agreement. That support can stabilize the insurer, but it also keeps the boundary between the insurance balance sheet and the wider business empire at the center of regulatory attention.

There is an uncomfortable asymmetry. If the asset exchanges work, the insurer may gradually regain distribution confidence while the parent absorbs or reallocates assets. If they fail, the insurer bears the reputational cost first because policyholders and distributors evaluate the entity that issued the contract, not only the ultimate owner.

The investigation also raises a governance question that cannot be solved by a higher sales bonus. Related-party classification is a process question. The company must show that the people identifying investments, underwriting credit and approving disclosures can challenge the commercial logic of transactions linked to affiliates. A control-remediation plan is credible only when it changes who can say no.

That is another reason to resist a simple “sales plunge amid probe” narrative. The sales decline is an observable outcome, but the economically decisive variable is the quality of the control system behind future asset growth. A penalty would matter financially; a finding that the process remains unreliable would matter strategically.

The impact is therefore indirect rather than a public-equity price reaction. The verified record contains no listed-share price to serve as a clean verdict. The relevant prices are embedded in the economics of distribution, the cost of replacement assets, the terms of parent support and rating agencies’ assessment of execution. Those prices move slowly, but they can compound.

Three Horizons and Three Scenarios

In the short term, sentiment and liquidity dominate. The base case is that distributors remain cautious while Delaware Life seeks approval for the up-to-$6.5 billion exchange and works toward the affiliated-asset targets it has disclosed. Sales run below the 2025 pace, but the existing asset base and investment income keep earnings positive. The trigger for improvement is not a general rally in annuities; it is a clean sequence of approvals, filings and updated affiliated-asset disclosures.

The upside case is a fast restoration of confidence. It would require the exchange to close, affiliated assets to move toward approximately 20%–25% by year-end and below 10% by June 30, 2027, replacement assets to preserve credit quality and returns, and regulators and rating agencies to acknowledge that control weaknesses have been fixed. In that case, sales could recover before the balance sheet fully normalizes because distributors often need evidence of direction before they need evidence of perfection.

The downside case is a feedback loop. Approval is delayed, the asset exchange produces lower yields or requires more capital, sales remain weak, and the investigations lead to penalties or judgments that exceed current assumptions. S&P and Fitch have identified execution, governance, reporting and credit-risk concerns as pressure points. The result would be a lower-growth insurer with a higher cost of distribution and less flexibility to compete for new annuity premiums.

Over the medium term, fundamentals determine whether the sales decline becomes visible in earnings. The key ratio is not sales alone but sales relative to the existing asset base and capital. If sales remain around half-year levels while admitted assets rise only through investment returns and retained earnings, the company may preserve current profitability but lose operating leverage. If new business returns without a deterioration in the 6.85% investment-earned rate or the capital position, the franchise may absorb the episode.

Over the long term, the issue is structural: can a life insurer use private credit and affiliate relationships without weakening the transparency that distributors and supervisors require? If the answer is yes, Delaware Life’s episode becomes a costly but contained control failure. If the answer is no, the company’s pre-probe growth model will not return, even if the investigations close.

The decisive data points are clear. Watch the approval and closing status of the up-to-$6.5 billion exchange, the affiliated-assets percentage against the company’s 20%–25% and below-10% targets, the next comparable sales disclosure, the risk-based capital ratio and rating-agency outlooks. The signal that would most clearly disprove the bearish franchise reading is a return to prior sales momentum accompanied by a sustained reduction in affiliated exposures and the removal of negative rating language. Until that combination appears, the evidence points to a cyclical sales shock sitting on top of a structural governance test.

Delaware Life is not facing a demonstrated solvency event in the available record. It is facing something more gradual: a need to prove that the controls behind its growth can be trusted again. The sales decline is the first market price of that proof.

Explore more exclusive insights at nextfin.ai.

Insights

What are related-party investments?

What triggered Delaware Life's probe?

Why did annuity sales slow in 2026?

Why were assets reclassified?

What is the TWG asset exchange plan?

How strong is Delaware Life's capital?

Why do ratings agencies watch sales?

Did banks pause Delaware Life sales?

Can annuity demand offset lost sales?

What risks does private credit create?

How might policyholders be affected?

What could delay the asset exchange?

Could the probe change insurance rules?

How does distribution shape growth?

What would restore distributor trust?

How does Delaware compare with rivals?

What signals would restore confidence?

Search, ask or analyze anything...